AUSTEDO has a differentiated pharmacokinetic (PK) profile
vs tetrabenazine1

AUSTEDO features deuterium, which extends the half-life of active therapeutic metabolites (~9-10 hours)1-3:

  • Helps maintain more consistent drug levels, independent of individual patient metabolism1-4

Plasma Concentrations of Alpha and Beta Metabolites over 24 Hours—PK Model1

Plasma   Concentrations of Alpha and   Beta Metabolites Over 24   hours-Pharmacokinetic (PK) Model. 3 Peaks = Tetrabenazine 3 times a day   vs 2 Peaks = AUSTEDO®   (deutetrabenazine) tablets   twice daily. The correlation   between plasma levels and   clinical efficacy has not been   established. Plasma   Concentrations of Alpha and   Beta Metabolites Over 24   hours-Pharmacokinetic (PK) Model. 3 Peaks = Tetrabenazine 3 times a day   vs 2 Peaks = AUSTEDO®   (deutetrabenazine) tablets   twice daily. The correlation   between plasma levels and   clinical efficacy has not been   established.

Slower rate of metabolism allows for twice-
daily dosing of AUSTEDO

The correlation between plasma levels and clinical efficacy has not been established.

  • Twice-daily dosing of AUSTEDO showed a slower rate of rise, lower peak-to-trough fluctuations, and reduced Cmax vs tetrabenazine1

PK simulations of area under the curve (AUC) matched exposure to active metabolites based on dosing regimens of AUSTEDO (9 mg twice daily) and tetrabenazine (12.5 mg 3 times a day) at steady state.1

Deuteration of AUSTEDO allows for more consistent drug levels. VMAT2 inhibition with AUSTEDO can help regulate dopamine function, which is a key factor for control of movement1‑4

VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 2. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 3. Tung R. The development of deuterium-containing drugs. Innov Pharm Technol. 2010;32(32):24-28. 4. Frank S, Testa CM, Stamler D, et al.; Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40-50.